\
&
Contact us
This was 2 years ago
Locationvirtual
ProgrammesEPOS-BE, the Belgian node of the European Plate Observing System (EPOS), organises a webinar on the European Plate Observing System and the Belgian national node.
The programme will introduce the Pan-European research infrastructure EPOS, its mission, and its significant achievements, with a special focus on the value it provides to users and data providers. It will present the history and activities of EPOS-BE, the Belgian Node of the infrastructure.
We will delve into some of the most relevant scientific use cases for the Belgian solid Earth science community, chosen from the fields of GNSS, satellite data, seismology and anthropogenic hazards, and offer a live walkthrough of the EPOS data portal, which will offer insights on how to visualise and combine different types of data.
The event is intended to provide practical information for the Belgian scientists to make the most of this innovative infrastructure and boost their research by discovering and combining new data. It will include an interactive session for attendees to share their feedback, ask questions and provide their point of view on the evolution of the EPOS infrastructure.
Target audience: researchers, students and data professionals in solid earth science
Registration for the webinar is required by 21 November 2023.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.